Literature DB >> 7827293

Clinical characteristics and proliferating activity of intrahepatic cholangiocarcinoma.

K Ohashi1, Y Nakajima, M Tsutsumi, H Kanehiro, T Fukuoka, M Hisanaga, J Taki, D Nakae, Y Konishi, H Nakano.   

Abstract

To assist in the development of new approach to the palliation and treatment of intrahepatic cholangiocarcinomas, we classified tumours into mass-forming (MF), peri-ductal extension (PD), and spicula-forming (SF) types in 14 subjects who underwent surgical treatment. Lymph node metastasis and microscopic lymphatic invasion were pronounced in the PD and SF types. Furthermore, in SF type tumours the incidence of microscopic vascular and perineural invasion was high. The proliferating cell nuclear antigen labelling index, a reflection of the proliferation rate of tumour cells, was significantly higher in PD and SF types than in the MF type. The prognosis associated with the MF type tended to be better than that of the other two types. For the MF type, liver resection with tumour free margins must be performed, whereas for the PD and SF types, aggressive treatment, that is a combination of extensive liver resection, lymph node dissection, and effective adjuvant anti-cancer therapy should be provided to aim at life-long cure.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7827293     DOI: 10.1111/j.1440-1746.1994.tb01271.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  6 in total

1.  Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver.

Authors:  A Tannapfel; L Weinans; F Geissler; A Schütz; A Katalinic; F Köckerling; J Hauss; C Wittekind
Journal:  Dig Dis Sci       Date:  2000-02       Impact factor: 3.199

2.  Histologic factors affecting prognosis following hepatectomy for intrahepatic cholangiocarcinoma.

Authors:  T Uenishi; K Hirohashi; S Kubo; T Yamamoto; H Hamba; H Tanaka; H Kinoshita
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

3.  Intrahepatic cholangiocarcinoma: report of 272 patients compared with 5,829 patients with hepatocellular carcinoma.

Authors:  Xin-Da Zhou; Zhao-You Tang; Jia Fan; Jian Zhou; Zhi-Quan Wu; Lun-Xiu Qin; Zeng-Chen Ma; Hui-Chuan Sun; Shuang-Jian Qiu; Yao Yu; Ning Ren; Qing-Hai Ye; Lu Wang; Sheng-Long Ye
Journal:  J Cancer Res Clin Oncol       Date:  2009-03-18       Impact factor: 4.553

4.  Clinicopathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic cholangiocarcinoma.

Authors:  Shohachi Suzuki; Takanori Sakaguchi; Yoshihiro Yokoi; Kazuya Okamoto; Kiyotaka Kurachi; Yasuo Tsuchiya; Takuya Okumura; Hiroyuki Konno; Satoshi Baba; Satoshi Nakamura
Journal:  World J Surg       Date:  2002-03-26       Impact factor: 3.352

Review 5.  Current status of intrahepatic cholangiocarcinoma.

Authors:  Jian Yang; Lu-Nan Yan
Journal:  World J Gastroenterol       Date:  2008-11-07       Impact factor: 5.742

6.  Ki-ras point mutations and proliferation activity in biliary tract carcinomas.

Authors:  K Ohashi; M Tstsumi; Y Nakajima; H Nakano; Y Konishi
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.